Canada
· Delayed Price · Currency is CAD Medicenna Therapeutics Statistics
Total Valuation
Medicenna Therapeutics has a market cap or net worth of CAD 103.24 million. The enterprise value is 72.99 million.
| Market Cap | 103.24M |
| Enterprise Value | 72.99M |
Important Dates
The next estimated earnings date is Friday, February 7, 2025.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Medicenna Therapeutics has 78.22 million shares outstanding. The number of shares has increased by 4.04% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 78.22M |
| Shares Change (YoY) | +4.04% |
| Shares Change (QoQ) | +4.37% |
| Owned by Insiders (%) | 15.18% |
| Owned by Institutions (%) | 0.22% |
| Float | 50.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.07 |
| P/TBV Ratio | 5.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.74 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.33 |
Financial Position
The company has a current ratio of 11.40, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.40 |
| Quick Ratio | 11.13 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -122.71% and return on invested capital (ROIC) is -52.52%.
| Return on Equity (ROE) | -122.71% |
| Return on Assets (ROA) | -37.80% |
| Return on Invested Capital (ROIC) | -52.52% |
| Return on Capital Employed (ROCE) | -61.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.67M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.31M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +185.71% in the last 52 weeks. The beta is 1.11, so Medicenna Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | +185.71% |
| 50-Day Moving Average | 1.60 |
| 200-Day Moving Average | 2.02 |
| Relative Strength Index (RSI) | 34.77 |
| Average Volume (20 Days) | 68,029 |
Short Selling Information
The latest short interest is 222,810, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 222,810 |
| Short Previous Month | 150,128 |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.45% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.35M |
| Pretax Income | -26.68M |
| Net Income | -26.68M |
| EBITDA | -18.33M |
| EBIT | -18.35M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
The company has 30.43 million in cash and 176,000 in debt, giving a net cash position of 30.25 million or 0.39 per share.
| Cash & Cash Equivalents | 30.43M |
| Total Debt | 176,000 |
| Net Cash | 30.25M |
| Net Cash Per Share | 0.39 |
| Equity (Book Value) | 20.05M |
| Book Value Per Share | 0.26 |
| Working Capital | 29.82M |
Cash Flow
In the last 12 months, operating cash flow was -16.81 million and capital expenditures -33,000, giving a free cash flow of -16.85 million.
| Operating Cash Flow | -16.81M |
| Capital Expenditures | -33,000 |
| Free Cash Flow | -16.85M |
| FCF Per Share | -0.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Medicenna Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.04% |
| Shareholder Yield | -4.04% |
| Earnings Yield | -25.84% |
| FCF Yield | -16.32% |
Stock Splits
The last stock split was on March 3, 2017. It was a reverse split with a ratio of 0.0714285.
| Last Split Date | Mar 3, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.0714285 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |